Clinical library

The Clinical library includes videos, clinical papers and case studies which support the clinical trial data and real world experience of healthcare professionals using VARGATEF®.

Novello et al.
SUMMARY: The LUME-Lung 1 trial demonstrated a significant overall survival (OS) advantage for nintedanib plus docetaxel compared with placebo plus docetaxel as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC) and adenocarcinoma histology. Patient-reported outcomes (PROs) for symptoms and health-related quality of life (QoL) are reported here.
Reck et al.
SUMMARY: The combination of nintedanib/docetaxel was evaluated in LUME-Lung 1. Adverse events (AEs) seen with existing anti-angiogenic agents were evaluated. AEs associated with other agents were less pronounced with nintedanib + docetaxel.
Dr Martin Reck, Rolf Kaiser, Anders Mellemgaard
SUMMARY: The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).
Gottfried et al.
SUMMARY: In the phase III LUME-Lung 1 study, overall survival (OS) was significantly longer with nintedanib/docetaxel than with placebo/docetaxel in all adenocarcinoma patients and those with time from start of FLT (TSFLT) <9 months.
Sohita Dhillon
SUMMARY: Nintedanib is the first antiangiogenic agent to have shown a survival benefit in the second-line treatment of these patients. Health-related quality of life (HR-QOL) was not adversely affected with the addition of nintedanib to docetaxel in the overall population or in the adenocarcinoma subgroup. Nintedanib combination therapy had a generally manageable tolerability profile.
Patient case 1: Early progressing disease & administration of vargatef until PD
Dosing regimen
Dosing adjustments
Watch the mechanism of action video
LUME-Lung 1 trial: efficacy, VARGATEF® + Docetaxel vs Placebo + Docetaxel
FooterMobile Back to Top